Skip to main content
Premium Trial:

Request an Annual Quote

Waiting, Waiting

Supply chain bottlenecks are contributing to the long wait for COVID-19 testing results in the US, Reuters reports.

It adds that as US labs typically rely on automated systems to conduct testing, they need to use particular reagents and other tools that work with the systems they have. Because of this, when testing rates go up, there can be shortages of needed supplies. "The vendors are in an impossible situation right now where they can't say yes to everyone," Geoffrey Baird, who runs the medical laboratory at the University of Washington, tells Reuters. Four companies — Cepheid, Hologic, Roche, and Abbott Laboratories — provide much of the COVID-19 testing capacity in the US, according to Reuters.

Reuters notes that Congress has put funds toward boosting COVID-19 testing, but not in a way that will alleviate supply chain problems, as states have sought machines from the same companies. Some labs, it says, have obtained machines from multiple companies and switch between them based on what supplies are available and others are using multi-step tests, which are more labor intensive.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.